You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 12, 2024

~ Buy the RADICAVA ORS (edaravone) Drug Profile, 2024 PDF Report in the Report Store ~

RADICAVA ORS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Radicava Ors, and when can generic versions of Radicava Ors launch?

Radicava Ors is a drug marketed by Mitsubishi Tanabe and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in RADICAVA ORS is edaravone. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Radicava Ors

A generic version of RADICAVA ORS was approved as edaravone by DR REDDYS on May 6th, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RADICAVA ORS?
  • What are the global sales for RADICAVA ORS?
  • What is Average Wholesale Price for RADICAVA ORS?
Drug patent expirations by year for RADICAVA ORS
Drug Prices for RADICAVA ORS

See drug prices for RADICAVA ORS

Recent Clinical Trials for RADICAVA ORS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Auzone Biological Technology Pty LtdPhase 1
Mitsubishi Tanabe Pharma CorporationPhase 1
Brain CanadaPhase 2

See all RADICAVA ORS clinical trials

Paragraph IV (Patent) Challenges for RADICAVA ORS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RADICAVA ORS Oral Suspension edaravone 105 mg/5 mL 215446 1 2023-04-20

US Patents and Regulatory Information for RADICAVA ORS

RADICAVA ORS is protected by five US patents and two FDA Regulatory Exclusivities.

Patents protecting RADICAVA ORS

Edaravone suspension for oral administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Edaravone suspension for oral administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting RADICAVA ORS

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Exclusivity Expiration: ⤷  Sign Up

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for RADICAVA ORS

When does loss-of-exclusivity occur for RADICAVA ORS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6967
Patent: SUSPENSIÓN EDARAVONE PARA ADMINISTRACIÓN ORAL
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 19369843
Patent: Edaravone suspension for oral administration
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2021008197
Patent: suspensão de edaravone para administração oral
Estimated Expiration: ⤷  Sign Up

China

Patent: 2969459
Patent: 用于口服给药的依达拉奉混悬剂 (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION)
Estimated Expiration: ⤷  Sign Up

Patent: 7379369
Patent: 依达拉奉在制备用于治疗肌萎缩侧索硬化的口服混悬剂中的用途 (Application of edaravone in preparation of oral suspension for treating amyotrophic lateral sclerosis)
Estimated Expiration: ⤷  Sign Up

Patent: 7379370
Patent: 用于口服给药的依达拉奉混悬剂 (Edaravone suspension for oral administration)
Estimated Expiration: ⤷  Sign Up

Patent: 7398346
Patent: 用于口服给药的依达拉奉混悬剂 (Edaravone suspension for oral administration)
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 75085
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 75085
Patent: SUSPENSION D'ÉDARAVONE DESTINÉE À ÊTRE ADMINISTRÉE PAR VOIE ORALE (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 2773
Patent: השעיה של edaravone למינהל אוראלי (Edaravone suspension for oral administration)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 2020091036
Patent: 経口投与用エダラボン懸濁剤
Estimated Expiration: ⤷  Sign Up

Patent: 74502
Estimated Expiration: ⤷  Sign Up

Patent: 23087011
Patent: 経口投与用エダラボン懸濁剤 (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION)
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 21005144
Patent: SUSPENSION DE EDARAVONA PARA ADMINISTRACION ORAL. (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION.)
Estimated Expiration: ⤷  Sign Up

Patent: 23009973
Patent: SUSPENSION DE EDARAVONA PARA ADMINISTRACION ORAL. (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION.)
Estimated Expiration: ⤷  Sign Up

Patent: 24000663
Patent: SUSPENSION DE EDARAVONA PARA ADMINISTRACION ORAL. (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION.)
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 021550988
Patent: EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 202104365Q
Patent: EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 210087490
Patent: 경구 투여용 에다라본 현탁액
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 2031256
Patent: Edaravone suspension for oral administration
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RADICAVA ORS around the world.

Country Patent Number Title Estimated Expiration
Mexico 2024000663 SUSPENSION DE EDARAVONA PARA ADMINISTRACION ORAL. (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION.) ⤷  Sign Up
European Patent Office 3875085 SUSPENSION D'ÉDARAVONE DESTINÉE À ÊTRE ADMINISTRÉE PAR VOIE ORALE (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION) ⤷  Sign Up
Denmark 3875085 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.